A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Elimusertib (Primary)
- Indications Alveolar soft part sarcoma; Ewing's sarcoma; Lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 27 Jun 2024 Planned End Date changed from 30 Jun 2024 to 31 Dec 2024.
- 27 Jun 2024 Planned primary completion date changed from 30 Jun 2024 to 31 Dec 2024.
- 06 Jun 2023 Initial phase 1 results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.